Abstract: Lipolytic enzymes which improve the properties of dough or baked products generally have a high activity towards lipids which are capable of forming a hexagonal phase, and a screening method was developed on this basis. The improved properties may include a larger loaf volume, an improved shape factor, an improved crumb structure, reduced dough stickiness, improved dough stability and/or improved tolerance towards extended proofing.

Abstract: Assessing quality of feedstock is provided and may be useful for determining quality of feed (such as corn kernels). The assessment determines endogenous enzyme activity within the feedstock, which correlates with total ethanol yields in raw starch hydrolysis (non-cooked) systems. In some embodiments, a sample containing flour (ground feedstock) is provided. In some cases, flour is diluted in water and buffered with a phosphate buffered solution. The buffered flour solution is contacted with a molecule, or fluorescent dye, such as fluorescein diacetate and/or difluorofluorescein that is altered by enzymatic (esterase) activity in a detectable fashion. Enzyme activity may be facilitated using an incubator. The detectible alteration may be measured using a fluorometer. In some embodiments, two incubations and fluorescence measurements can be performed.

Abstract: This invention relates to methods for determining the activity of Lp-PLA2 in at least one sample from an animal. The invention also relates to methods for determining the inhibition of Lp-PLA2 activity in samples from animals that are administered an Lp-PLA2 inhibitor.

Abstract: A process for detecting and/or identifying, in a biological sample, bacteria exhibiting a resistance to carbapenems by producing carbapenemase, includes: a) contacting said sample with a reaction medium including at least one carbapenem-class antibiotic, and cloxacillin; b) incubating the whole so as to allow the bacteria to grow; and c) detecting the strains exhibiting enzymatic resistance to carbapenems. Advantageously, the medium employed in step a) also contains phenylalanine-arginine-beta-naphthylamide (PAbetaN).

Abstract: Methods for cancer diagnosis, making decisions on appropriate cancer treatment, awareness of a predisposition to cancer and potential cancer prevention, and monitoring of cancer therapy by measuring the activity of PMPMEase.

Abstract: The invention relates to agents containing esterases, and to the use thereof for dressing fibres, in particular, artificial fibres, washing and cleaning agents comprising esterases and corresponding washing and cleaning methods, in addition to additional technical areas of application. The invention also relates to the use of esterases for protecting against or reducing and/or preventing pilling, preferably in textiles, particularly plastic fibres, more preferably polyester fibres, in addition to the use of esterases for separating the plastics, in particular, polyester compounds. The invention further relates to novel esterases and to sufficiently related proteins and to derivatives thereof, agents containing them and to the use thereof.

Abstract: The invention relates to a method of detecting and quantifying small peptides derived from proteins from a range of different clinical samples using the Selective Reaction Monitoring (SRM) profiling technique. By targeting these unique peptides which specifically identify particular proteins, the present invention enables multiple samples to be run in a multiplexed fashion in order to identify, diagnose, quantitate and profile a full range of benign and pathologic entities, including but not limited to, the complete range of cancers and the spectrum of inflammatory diseases, including inflammatory cell typing and bone marrow cell typing. The SRM assay is capable of performing clinical blood typing and it can also act as a diagnostic test to identify women at highest risk for cervical cancer base on Human Papillomavirus (HPV) testing.

Abstract: The invention presents a method of identifying natural biopolymer—a protein, DNA, RNA in biological fluids and environmental objects, which is based only on the structure of the biopolymer and does not require pathogen genome sequencing, or animals vaccination by biopolymer-antigen. For this purpose the biopolymer itself is taken—a protein, DNA, or RNA, that is fragmented with enzyme to oligomer fragments—a mixture of oligopeptides, oligonucleotides DNA mixture, mixture of RNA oligonucleotides, without dividing the mixture into individual components, then carboxylation of structure in oligomer components is performed by acylation or alkylation.

Abstract: Apparatus for detecting the presence of foreign substances in a beverage. The apparatus for detecting the presence of Gamma-hydroxybutyrate or other drugs in a beverage comprises apparatus wherein cobalt nitrate, oxammonium chloride/ferric chloride, oxammonium sulphate/ferric chloride, 5% ferric chloride, saturated potassium dichromate, toluene/cobalt thiocyanate, chromium (IV) oxide/sulphuric acid carbodiimide salts in combination with oxammonium salts and ferric chloride, or lacmoid is supported on a substrate. The apparatus for detecting the presence of ketamines or other drugs in a beverage comprises apparatus wherein modified-Dragendorff Reagent is supported on a substrate.

Abstract: The present invention relates to the use of reagent for permanently inactivating nucleases wherein the reagent comprises an oxidizing agent, a protein denaturant and optionally a pH adjustor and to a method for permanently inactivating nucleases using said reagent.

Abstract: Provided herein are methods, test units, systems, assays and kits for qualitative and/or quantitative detection of microorganisms or microbes. Some aspects of the invention utilize a test strip comprising a test area and a self-calibrating control area that permits quantitative measurements to be obtained rapidly at the test site. The test strip is ready-to-use and does not require any preparation. The present systems and methods provide valuable tools for sensitive early detection of microbial contamination.

Abstract: The present invention relates to the visualization of acidic organelles based upon organelle enzyme activity. The organelle substrates of the invention are specific for enzyme activity of the organelle and label these organelles, such as lysosomes, rendering them visible and easily observed. Substrates of the present invention include substrates that produce a fluorescent signal. The fluorogenic acidic organelle enzyme substrates of this invention are designed to provide high fluorescence at low pH values and are derivatized to permit membrane permeation through both outer and organelle membranes of intact cells and can be used for staining cells at very low concentrations. They can be used for monitoring enzyme activity in cells at very low concentrations and are not toxic to living cells or tissues.

Abstract: This invention relates to methods for using Lipoprotein-associated Phospholipase A2 (Lp-PLA2) to care for subjects in an acute care setting. Specifically, Lp-PLA2 can be used determine if a subject having a vascular event, such as a stroke or heart attack, will benefit from therapy in the acute care setting. Moreover, it relates to methods of assessing risk and severity of a stroke by evaluating Lp-PLA2 levels alone or in combination with other assessments. In addition the invention relates to methods of using Lp-PLA2 to assess the functional outcome in a subject having a vascular event such as a stroke or heart attack.

Abstract: This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.

Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.

Abstract: Compositions that comprise water, a first indicator reagent that can be converted by a first biological activity to a first biological derivative, and a plurality of particles are provided. The first indicator reagent can comprise a fluorogenic enzyme substrate having a fluorophore selected from the group consisting of umbelliferone, 7-aminocoumarin, ?-naphthylamine, ?-naphthol, fluorescein, resorufin, 9H-(1,3-dichloro-9,9-dimethyl acridin-2-one), rhodamine 110, a derivative of any of the foregoing fluorophores, and a combination of any of the foregoing fluorophores. The particles are capable of receiving and retaining the first biological derivative from an aqueous liquid. The first biological derivative can be indicative of a microorganism. The compositions further can comprise a gelling agent. Methods of using the compositions to detect the presence or absence of a microorganism in a sample are also provided.

Abstract: This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.

Abstract: The present invention concerns the endonucleases capable of cleaving a target sequence located in a “safe harbor loci”, i.e. a loci allowing safe expression of a transgene. The present invention further concerns the use of such endonucleases for inserting transgenes into a cell, tissue or individual.

Abstract: The present invention discloses a method for assessment of previous ethanol exposure comprising the steps of: (i) obtaining a sample from the body of a subject; (ii) quantitatively determining the level of one or several bio-precursors of PEth (Formula I) and the level of the corresponding one or several PEth-homologues (Formula II) in the sample; and (iii) obtaining a ratio between the level of one or several bio-precursors of PEth and the level of the corresponding one or several PEth-homologues; wherein the subject is a human or animal. Additional related methods are also disclosed.

Abstract: In some aspects, the invention provides compositions and methods for inhibiting viral infection. In some aspects, the invention provides compositions and methods useful for identifying antiviral compounds.

Abstract: The invention concerns a method for monitoring the development of a disease in a patient, and for assessing the efficacy of a therapy influencing on the CD73 level or activity in the patient, in particular a cytokine therapy or a statin therapy. CD73 in a tissue fluid drawn from the patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.

Abstract: Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening (HTS) for identification of potential inhibitors of lysoPLD activity.

Abstract: A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability.

Abstract: The invention provides a compound of formula (I) as defined herein that is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, or diabetes and disorders and conditions associated therewith. The invention also provides a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. activity.

Abstract: The invention relates to a method for analysing ingredients, in particular lipids and/or vitamins and biological material ingredients, to methods of using relevant organic solvents or organic solvent mixtures, and to a spectrophotometer for measuring biological material ingredients. It is proposed to treat the biological materials with at least one organic solvent which extracts the ingredients, to convert the bi ological materials to a solidified form during the extraction, with the result that a solidified sediment and a liquid organic phase as the supernatant are formed, and to examine the extracted ingredients in the supernatant.

Abstract: The invention describes a method for assaying HCV NS3 protease activity using an NS3•4A protease molecule. The invention also provides a method for screening and identifying modulators of NS3 protease.

Abstract: A reaction medium for detecting and/or identifying methicillin-resistant Staphylococcus aureus (MRSA) bacteria includes a chromogenic substrate, a first antibiotic that belongs to the cephalosporin family and a second antibiotic that belongs to the aminoglycoside family.

Abstract: The present invention provides fluorogenic substrates and methods of use in detecting and analyzing phospholipase C isozyme (PLC) activity.

Abstract: A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability.

Abstract: Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Abstract: The disclosed subject matter relates to a force-clamp spectrometer that enables operation in constant force mode and allows for automated data acquisition and analysis, using feedback electronics and software. The disclosed subject matter also relates to methods of using the force-clamp spectrometer for the measurement of the dynamics of chemical reactions. The methods may include, but are not limited to, the measurement of the dynamics of substrate folding and unfolding, as well as bond cleavage and bond formation.

Abstract: The present invention relates to novel amino acid and nucleic acid sequences of yclic nucleotide-specific phosphodiesterases from the parasite Leishmania major. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the amino acid and nucleic acid sequences. The invention further relates to the use of these sequences, and of antibodies directed against these sequences, in the diagnosis and treatment of disorders related to the infection of Leishmania major, including the identification of compounds that form complexes with the polypeptides and nucleic acids of the present invention.

Abstract: The invention relates to Citrobacter phytases derived from Citrobacter amalonaticus, Citrobacter gillenii, and related phytases. The phytases belong to the acid histidine phosphatase family, are acid-stable, and expectedly of a high specific activity. The invention also relates to the corresponding DNA, the recombinant and wild-type production of the phytases, as well as the use thereof, in particular in animal feed.

Abstract: Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: where R1 and R2 are, independently, H or C1 to C3 alkyl; R3 and R4 are, independently C1 to C3 alkyl; and where R1 and R2, taken together, or R3 and R4, taken together, or both may be cycloalkyl; R5 is H, OH, or C1 to C6 alkyl; R6 is or C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R7 is C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R6 and R7, or R5, R6 and R7, taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

Abstract: The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.

Abstract: Methods are provided for making restriction endonucleases with reduced star activity by one or more targeted mutations to a catalytic site within the restriction endonuclease. Examples of modifications to restriction endonucleases with significant sequence identity with KpnI are provided and reduced star activity demonstrated.

Abstract: Disclosed are compounds that activate the human G-protein coupled receptor TAS2R48, and methods of using these compounds for identifying compounds that modulate the response of the TAS2R48 receptor. Compounds identified as modulators of the response of the receptor TAS2R48 may be used to decrease or mask the bitter taste of foods or drugs.

Abstract: Aortic valve stenosis (AS) is a chronic process related to a progressive mineralization of the aortic root and valve cusps. We found in human AS valves a high level of expression and enzymatic activity of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP-1), which correlated to the degree of mineralization. In vitro, inhibition of ENPP activity with ARL 67156 significantly reduced calcification of isolated valve interstitial cells. In a rat model of cardiovascular calcification, ARL 67156 significantly reduced calcification of the aortic root and valve cusps. This is the first study to demonstrate that increased expression and activity of ENPP-1 promotes the mineralization process in AS valves. Hence, inhibition of ectonucleotidase may represent a novel target of therapy for this frequent and serious cardiovascular disease.

Abstract: Disclosed are a method of treating or preventing a disorder in a mammal comprising administering to the mammal an adenosine receptor agonist or an adenosine receptor antagonist, either alone or in combination, in an amount effective to treat or prevent medial vascular or joint capsule calcification. Disclosed are methods of detecting or diagnosing a vascular or joint capsule calcification disorder, as well as a nucleic acid comprising a mutation in one or more exons of human NT5E selected from the group consisting of Exon 3, Exon 5, and Exon 9.

Abstract: The present invention is related to a method for detection of a biological target in an affinity assay, the method comprising the steps of providing a biological sample volume containing the biological target, adding a first capturing moiety to the biological sample volume comprising the biological target, wherein the first capturing moiety is adhered to a particle, concentration of the captured biological target into an elution volume that is smaller than the biological sample volume in step a), cleavage of the first capturing moiety or the biological target from the particle and direct or indirect detection and/or quantification of the biological target in a sandwich or competitive affinity assay format, wherein the biological target is associated with at least one capturing moiety, preferably at least two capturing moieties.

Abstract: The present invention relates to a method for identifying at least two groups of microorganisms expressing the same enzymatic activity, comprising the following steps: a) incubating said groups of microorganisms in a reaction medium comprising a first enzyme substrate and a second enzyme substrate, said first and second enzyme substrates being metabolized by the same enzymatic activity; b) identifying said groups of microorganisms.

Abstract: The invention provides inhibitors of influenza endonuclease activity and tools for their discovery.

Abstract: The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN1 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods.

Abstract: The present invention concerns an in vitro method for detecting an enzyme or a microorganism in a biological sample, comprising the steps of: a1) concentrating the microorganisms present in the biological sample, optionally after a a0) culture step of the microorganisms; b1) placing in suspension the microorganisms concentrated at step a1) in a solution containing at least one chromogenic or fluorogenic substrate capable of releasing a chromophore or fluorophore after hydrolysis by the enzyme to be detected; c1) detecting potential release of the chromophore or fluorophore obtained at step b1); the release of the chromophore or fluorophore detected at step c1) indicating the presence of the enzyme to be detected.

Abstract: The present invention relates to a method for specific and direct detection of Shiga toxin-producing Escherichia coli bacteria in a sample using a selective and differential isolation medium for Shiga toxin-producing Escherichia coli bacteria comprising at least one chromogenic agent and tellurite.

Abstract: A selective growth media for Campylobacter bacteria comprising nutrients, growth inhibitors for organisms other than Campylobacter including bile salts, Irgasan DP 300, sodium cefsulodin hydrate, cycloheximide and sodium cefoperazone, and one or more ingredients for absorbing oxygen. Also, selective plating media for Campylobacter bacteria comprising said growth media, a thickening agent and Aldol acetate.

Abstract: Lipolytic enzymes which improve the properties of dough or baked products generally have a high activity towards lipids which are capable of forming a hexagonal phase, and a screening method was developed on this basis. The improved properties may include a larger loaf volume, an improved shape factor, an improved crumb structure, reduced dough stickiness, improved dough stability and/or improved tolerance towards extended proofing.

Abstract: Materials and Methods are provided for the diagnosis, monitoring, and personalized treatments of gynecological cancers. The methods comprise determining levels of PLA2 activity in sample of tissue or fluid recovered from patient; elevated levels of PLA2 activity are consistent with epithelial ovarian cancer (EOC). These methods include assaying for PLA2 activity within tissue, ascites, blood, and other tissue forms by exposing the patient sample to a fluorogenic compound such as DBPC. The methods disclosed herein further include correlating the fluorogenic detection with a disease state in the patient, including diseases such as gynecological cancers, such as EOC. The methods comprise determining levels of total PLA2 activity, and of specific isoforms of PLA2 such as iPLA2, iPLA2?, cPLA2, among other isoforms.

Abstract: The present invention relates to methods of determining enzyme activity in a fluid, wherein the activity over time provides a viscosity-change in the fluid, by the use of a device (FIG. 1) equipped with at least one pressure sensor (FIG. 1 (4)) to determine the change in the fluid viscosity over time as a measure of the enzyme activity.

Abstract: The present invention provides a method for detecting a phytol-free chlorophyll derivative in a sample, comprising a step of detecting a fluorescent signal associated with the phytol-free chlorophyll derivative, wherein a fluorescent signal associated with chlorophyll or a phytol-containing chlorophyll derivative in the sample is quenched. The method may be used for quantifying activity of chlorophyllases and related enzymes in a sample without solvent fractionation of substrate and product.